{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T21:42:57Z","timestamp":1781905377143,"version":"3.54.5"},"reference-count":19,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T00:00:00Z","timestamp":1578873600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["analyticalsciencejournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Drug Testing and Analysis"],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The entire scalp hair of a self\u2010declared Kratom consumer of 3 grams per day was acquired during an ethical committee approved study. As no values of the concentration in hair of the two Kratom alkaloids mitragynine or 7\u2010hydroxymitragynine were found in the literature, an already established method for the analysis of benzodiazepines\/z\u2010substances was extended for the detection of mitragynine and 7\u2010hydroxymitragynine with LC\u2013MS\/MS, and successfully validated. The limits of detection and quantification for mitragynine were 2 pg\/mg and 4 pg\/mg, respectively. Those of 7\u2010hydroxymitragynine were 20 pg\/mg and 30 pg\/mg, respectively. The method was applied to the entire scalp hair, divided in 91 regions, of the study participant. A narrow mitragynine concentration distribution with values between 1054 pg\/mg and 2244 ng\/mg (mean 1517 ng\/mg) and no clear scalp region associated distribution pattern was obtained. 7\u2010Hydroxymitragynine was not detected in any hair sample. After validation, the method was established as routine and subsequently 300 samples (mainly abstinence controls for drugs of abuse) were analyzed, allowing the investigation of the prevalence of Kratom consumption in our population. None of the analyzed routine hair samples were positive for mitragynine or 7\u2010hydroxymitragynine, providing no evidence that Kratom consumption is prevalent in the investigated population.<\/jats:p>","DOI":"10.1002\/dta.2746","type":"journal-article","created":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T06:02:27Z","timestamp":1576216947000},"page":"280-284","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Development, validation, and application of an LC\u2013MS\/MS method for mitragynine and 7\u2010hydroxymitragynine analysis in hair"],"prefix":"10.1002","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8284-9467","authenticated-orcid":false,"given":"Ulf","family":"Meier","sequence":"first","affiliation":[{"name":"Department of Biomedical Engineering University of Basel Institute of Forensic Medicine  Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3843-9065","authenticated-orcid":false,"given":"Katja","family":"Mercer\u2010Chalmers\u2010Bender","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering University of Basel Institute of Forensic Medicine  Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2742-0422","authenticated-orcid":false,"given":"Eva","family":"Scheurer","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering University of Basel Institute of Forensic Medicine  Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz","family":"Dussy","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering University of Basel Institute of Forensic Medicine  Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,1,13]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00414-015-1279-y"},{"key":"e_1_2_5_3_1","first-page":"2421","article-title":"Pharmacokinetics of mitragynine in man","volume":"9","author":"Trakulsrichai S","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-017-4813-4"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainresbull.2016.05.004"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1021\/acscentsci.9b00141"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2017.03.007"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2009.12.003"},{"key":"e_1_2_5_9_1","unstructured":"Eidgen\u00f6ssisches Departement des Innern.Bet\u00e4ubungsmittelverzeichnisverordnung.2011;https:\/\/www.admin.ch\/opc\/de\/classified-compilation\/20101220\/index.html. Accessed 9 April 2019."},{"key":"e_1_2_5_10_1","unstructured":"European Monitoring Centre for Drugs and Drug Addiction.Kratom (Mitragyna speciosa) drug profile.http:\/\/www.emcdda.europa.eu\/publications\/drug-profiles\/kratom. Accessed 9 April 2019."},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2017.03.020"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2003.09.054"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(96)00714-5"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.6b00360"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0034-1368444"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2006-959578"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11419-009-0070-5"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.2679"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.2314"},{"issue":"3","key":"e_1_2_5_20_1","first-page":"185","article-title":"Anhang B zur Richtlinie der GTFCh zur Qualit\u00e4tssicherung bei forensisch\u2010toxikologischen Untersuchungen. Anforderungen and die Validierung von Analysemethoden","volume":"76","author":"Peters FT","year":"2009","journal-title":"Toxichem Krimtech"}],"container-title":["Drug Testing and Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fdta.2746","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dta.2746","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/dta.2746","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dta.2746","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T23:00:00Z","timestamp":1760396400000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/dta.2746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,13]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["10.1002\/dta.2746"],"URL":"https:\/\/doi.org\/10.1002\/dta.2746","archive":["Portico"],"relation":{},"ISSN":["1942-7603","1942-7611"],"issn-type":[{"value":"1942-7603","type":"print"},{"value":"1942-7611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,13]]},"assertion":[{"value":"2019-11-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}